Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPR-001
- Development stage
- Preclinical
- Lead developer
- CrossPoint Therapeutics
- Modality
- Gene Therapies
01
Overview
CPR-001 is an early-stage gene delivery candidate being developed by CrossPoint Therapeutics. It utilizes the company's proprietary Stealth-Body technology to enable tissue- and cell-specific targeting and RNA regulation. The platform is designed to provide precise control over therapeutic payload expression, potentially improving the safety and efficacy of genetic medicines by overcoming common challenges such as off-target effects and immune clearance. As of 2024, CPR-001 is in the research phase and is not yet listed in CrossPoint's formal clinical pipeline table, though it is highlighted as a key candidate in their R&D section.
Beyond the preview
Go deeper on CPR-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPR-001.